Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Schedule of Fair Value of Derivative Liability (Details) - Development Derivative Liability - Level 3 $ in Thousands	11 Months Ended
	Dec. 31, 2021 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value at inception on February 12, 2021	$ 0
Non-cash research and development expense	16,703
Cash receipts from SFJ	3,000
Change in the fair value of development derivative liability	(8,023)
Fair value at end of period	$ 27,726